Deakin University
Browse

Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement

Version 2 2024-06-13, 14:43
Version 1 2021-10-11, 08:17
journal contribution
posted on 2024-06-13, 14:43 authored by SJ Bagley, S Kothari, R Rahman, EQ Lee, GP Dunn, E Galanis, SM Chang, LB Nabors, MS Ahluwalia, R Stupp, MP Mehta, DA Reardon, SA Grossman, EP Sulman, JH Sampson, S Khagi, M Weller, TF Cloughesy, PY Wen, M Khasraw
Therapeutic advances for glioblastoma have been minimal over the past 2 decades. In light of the multitude of recent phase III trials that have failed to meet their primary endpoints following promising preclinical and early-phase programs, a Society for Neuro-Oncology Think Tank was held in November 2020 to prioritize areas for improvement in the conduct of glioblastoma clinical trials. Here, we review the literature, identify challenges related to clinical trial eligibility criteria and trial design in glioblastoma, and provide recommendations from the Think Tank. In addition, we provide a data-driven context with which to frame this discussion by analyzing key study design features of adult glioblastoma clinical trials listed on ClinicalTrials.gov as “recruiting” or “not yet recruiting” as of February 2021.

History

Journal

Clinical Cancer Research

Volume

28

Pagination

594-602

Location

Philadelphia, Pa.

ISSN

1078-0432

eISSN

1557-3265

Language

eng.

Publication classification

C1 Refereed article in a scholarly journal

Issue

4

Publisher

American Association for Cancer Research

Usage metrics

    Research Publications

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC